|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM040515680 |
| 003 |
DE-627 |
| 005 |
20231221151248.0 |
| 007 |
tu |
| 008 |
231221s1985 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0135.xml
|
| 035 |
|
|
|a (DE-627)NLM040515680
|
| 035 |
|
|
|a (NLM)4070323
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shenderey, K
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multi-centre general practice comparison of a fixed-dose combination of pivmecillinam plus pivampicillin with amoxycillin in respiratory tract infections
|
| 264 |
|
1 |
|c 1985
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.1985
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Seven-day courses of either 200 mg pivmecillinam plus 250 mg pivampicillin given twice daily or 250 mg amoxycillin given 3-times daily were compared in a multi-centre general practice study in 350 patients with symptoms of upper or lower respiratory tract infection. Patients were stratified into four diagnostic groups: sinusitis, otitis media, throat infections, and acute bronchitis, and randomly allocated to treatment within these groups. Assessments at 7 days showed no difference in overall clinical efficacy between the two treatments; however, patients with acute bronchitis showed a better response to pivmecillinam plus pivampicillin. After treatment, signs of infection were absent in 139 (79%) patients in the pivmecillinam plus pivampicillin group and in 143 (80%) patients in the amoxycillin group. Both treatments were well tolerated, adverse effects being reported in only 17 (9.8%) patients after pivmecillinam plus pivampicillin and 15 (8.6%) patients after amoxycillin. These were mainly associated with disturbances of the gastro-intestinal tract where reports of diarrhoea were twice as common after amoxycillin
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Pivampicillin
|2 NLM
|
| 650 |
|
7 |
|a 0HLM346LL7
|2 NLM
|
| 650 |
|
7 |
|a Amdinocillin Pivoxil
|2 NLM
|
| 650 |
|
7 |
|a 1WAM1OQ30B
|2 NLM
|
| 650 |
|
7 |
|a Ampicillin
|2 NLM
|
| 650 |
|
7 |
|a 7C782967RD
|2 NLM
|
| 650 |
|
7 |
|a Amoxicillin
|2 NLM
|
| 650 |
|
7 |
|a 804826J2HU
|2 NLM
|
| 650 |
|
7 |
|a Amdinocillin
|2 NLM
|
| 650 |
|
7 |
|a V10579P3QZ
|2 NLM
|
| 700 |
1 |
|
|a Marsh, B T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Talbot, D J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 4(1985), 5 vom: 23., Seite 300-5
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:4
|g year:1985
|g number:5
|g day:23
|g pages:300-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1985
|e 5
|b 23
|h 300-5
|